Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 14;10(10):3465-3483.
doi: 10.1016/j.ekir.2025.07.008. eCollection 2025 Oct.

Outcomes After Kidney Transplantation in Antineutrophil Cytoplasmic Autoantibody-Associated Renal Vasculitis

Marine Dekervel  1 , Priscille Traversat  1 , Philippe Gatault  2 , Léonard Golbin  3 , Antoine Thierry  4 , Valérie Chatelet  5 , Sophie Caillard  6 , Anna Duval  6 , Emilie Cornec-Le Gall  7 , Martin Planchais  1 , Agnès Duveau  1 , Dominique Bertrand  8 , Jean-Philippe Rerolle  9 , Cyrille Garrouste  10 , Dany Anglicheau  11 , Maïté Jaureguy  12 , Fabien Duthe  4 , Jean-François Augusto  1   13 , Benoit Brilland  1   13
Affiliations

Outcomes After Kidney Transplantation in Antineutrophil Cytoplasmic Autoantibody-Associated Renal Vasculitis

Marine Dekervel et al. Kidney Int Rep. .

Abstract

Introduction: Antineutrophil cytoplasmic autoantibody (ANCA)-associated renal vasculitis (AAV) glomerulonephritis (GN) (AAV-GN) frequently leads to end-stage kidney disease (ESKD). Optimal management for patients with AAV-GN receiving a kidney transplantation (KT) remains poorly characterized. We compared posttransplant outcomes between patients with AAV-GN and controls in the modern era of immunosuppressive therapy.

Methods: This multicenter retrospective study included 206 adult patients with AAV-GN and 412 matched controls who underwent KT between 2005 and 2023 in 12 French transplant centers. We compared the incidence of delayed graft function (DGF), graft failure, AAV relapses, acute rejection, and mortality between groups; and analyzed risk factors using multivariable models.

Results: DGF incidence and kidney function up to 5 years after KT were similar between groups. Patients with AAV-GN showed a trend toward poorer graft survival (hazard ratio [HR] = 1.55, P = 0.077) and significantly lower overall survival (HR = 1.48, P = 0.034). AAV relapses occurred in 15 patients with AAV-GN (7.3%), significantly impacting graft survival (P = 0.008). ANCA positivity at KT tended to be associated with higher relapse risk (HR = 4.17, P = 0.065) and was associated with lower rejection risk (HR = 0.31, P = 0.016). Acute rejection incidence was comparable between groups. Azathioprine (AZA) maintenance therapy was associated with increased rejection (HR = 3.733, P = 0.012) and graft failure (HR = 3.73, P = 0.007 < 0.001). Although patients with AAV-GN were waitlisted later than controls, no specific transplant timing was associated with improved outcomes.

Conclusion: Although KT offers patients with AAV-GN short-term outcomes similar to controls, they face higher long-term risk of graft failure and mortality. ANCA status at transplantation may help predict immunological events, emphasizing the need for careful evaluation and monitoring, but without delaying the process. As for other nephropathies, AZA should be avoided as maintenance therapy in patients with AAV-GN. These findings highlight the need for tailored posttransplant management in patients with AAV-GN.

Keywords: ANCA; glomerulonephritis; kidney transplantation; outcomes; vasculitis.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Estimated glomerular filtration rate (eGFR) evolution after kidney transplantation. Data are represented as mean ± SD. AAV-GN, ANCA-associated vasculitis with glomerulonephritis; ANCA, antineutrophil cytoplasmic autoantibody; eGFR, estimated glomerular filtration rate.
Figure 2
Figure 2
Event-free survival after kidney transplantation. Cumulative incidence of (a) graft failure, (b) relapses or (c) acute rejection, and (d) overall survival. AAV-GN, ANCA-associated vasculitis with glomerulonephritis.
See this image and copyright information in PMC

References

    1. Sinico R.A., Di Toma L., Radice A. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev. 2013;12:477–482. doi: 10.1016/j.autrev.2012.08.006. - DOI - PubMed
    1. Kronbichler A., Shin J.I., Lee K.H., et al. Clinical associations of renal involvement in ANCA-associated vasculitis. Autoimmun Rev. 2020;19 doi: 10.1016/j.autrev.2020.102495. - DOI - PubMed
    1. Sachez-Alamo B., Moi L., Bajema I., et al. Long-term outcome of kidney function in patients with ANCA-associated vasculitis. Nephrol Dial Transplant. 2024;39(9):1483–1493. - PMC - PubMed
    1. Boud’hors C., Riou J., Fage N., et al. Adding 6-month parameters for the prediction of kidney prognosis in ANCA-associated glomerulonephritis. Clin Kidney J. 2023;16 doi: 10.1093/ckj/sfad157. - DOI - PMC - PubMed
    1. Allen A., Pusey C., Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 1998;9:1258–1263. doi: 10.1681/ASN.V971258. - DOI - PubMed

LinkOut - more resources